LOVE TED W — SEC insider filings

SEC reporting owner CIK 1188919. 36 insider filings on record with FilingPulse; latest filed 2026-09-28.

Transaction summary — filings shown

Covers all 36 filings on record, filed 2020-08-17 to 2026-09-28. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
Global Blood Therapeutics, Inc. (GBT)President and CEO, Director12——68
Seagen Inc. (SGEN)Director5——13
GILEAD SCIENCES, INC. (GILD)Director4——8
Royalty Pharma plc (RPRX)Director7——7
Jazz Pharmaceuticals plc (JAZZ)Director3——4
Structure Therapeutics Inc. (GPCR)Director4——4
LISATA THERAPEUTICS, INC. (LSTA)Director1———

Insider filings — LOVE TED W

FiledFormIssuerReported transactionsSource
2026-09-283LISATA THERAPEUTICS, INC. (LSTA)Holdings only — no transactions reportedEDGAR
2026-09-024Jazz Pharmaceuticals plc (JAZZ)Tax withholding (F): 6 @ $244.06 · Tax withholding (F): 737 @ $241.39EDGAR
2026-08-074Jazz Pharmaceuticals plc (JAZZ)Grant/award (A): 1,605 @ $0EDGAR
2026-06-184Structure Therapeutics Inc. (GPCR)Grant/award (A): 39,453 (derivative) @ $0EDGAR
2026-06-084Royalty Pharma plc (RPRX)Grant/award (A): 4,545 @ $0EDGAR
2026-05-044GILEAD SCIENCES, INC. (GILD)Grant/award (A): 1,146 @ $0 · Grant/award (A): 4,884 (derivative) @ $0EDGAR
2026-03-024Jazz Pharmaceuticals plc (JAZZ)Grant/award (A): 1,527 @ $0EDGAR
2025-06-254Structure Therapeutics Inc. (GPCR)Grant/award (A): 51,804 (derivative) @ $0EDGAR
2025-05-144Royalty Pharma plc (RPRX)Grant/award (A): 7,614 @ $0EDGAR
2025-05-084GILEAD SCIENCES, INC. (GILD)Grant/award (A): 1,516 @ $0 · Grant/award (A): 6,809 (derivative) @ $0EDGAR
2024-06-274Structure Therapeutics Inc. (GPCR)Grant/award (A): 33,595 (derivative) @ $0EDGAR
2024-06-104Royalty Pharma plc (RPRX)Grant/award (A): 9,293 @ $0EDGAR
2024-05-094GILEAD SCIENCES, INC. (GILD)Grant/award (A): 2,310 @ $0 · Grant/award (A): 12,648 (derivative) @ $0EDGAR
2024-02-064GILEAD SCIENCES, INC. (GILD)Grant/award (A): 512 @ $0 · Grant/award (A): 2,996 (derivative) @ $0EDGAR
2023-12-154Seagen Inc. (SGEN)Disposition to issuer (D): 4,255 @ $229 · Disposition to issuer (D): 4,460 (derivative) · Disposition to issuer (D): 3,462 (derivative) · Disposition to issuer (D): 3,676 (derivative) · Disposition to issuer (D): 449 (derivative) · Disposition to issuer (D): 2,044 (derivative)EDGAR
2023-08-044Structure Therapeutics Inc. (GPCR)Grant/award (A): 75,000 (derivative) @ $0EDGAR
2023-06-264Royalty Pharma plc (RPRX)Grant/award (A): 7,747 @ $0EDGAR
2023-06-024Seagen Inc. (SGEN)Grant/award (A): 2,044 @ $0EDGAR
2022-10-064Global Blood Therapeutics, Inc. (GBT)Disposition to issuer (D): 576,318 · Disposition to issuer (D): 119,650 · Disposition to issuer (D): 119,650 · Disposition to issuer (D): 102,000 · Disposition to issuer (D): 2,500 · Disposition to issuer (D): 2,500 · +12 moreEDGAR
2022-09-294Global Blood Therapeutics, Inc. (GBT)Gift (G): 221,200 @ $0 · Gift (G): 35,300 @ $0 · Gift (G): 17,650 @ $0 · Gift (G): 17,650 @ $0 · Option exercise (M): 18,291 @ $16.40 · Option exercise (M): 18,291 (derivative) @ $0EDGAR
2022-09-064Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 9,444 · Option exercise (M): 9,109 · Tax withholding (F): 9,200 @ $68.15 · Option exercise (M): 9,444 (derivative) @ $0 · Option exercise (M): 9,109 (derivative) @ $0EDGAR
2022-08-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 20,205 · Tax withholding (F): 10,018 @ $32.40 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0EDGAR
2022-06-244Royalty Pharma plc (RPRX)Grant/award (A): 6,328 @ $0EDGAR
2022-05-174Seagen Inc. (SGEN)Grant/award (A): 1,503 @ $0 · Grant/award (A): 3,676 (derivative) @ $0EDGAR
2022-03-034Global Blood Therapeutics, Inc. (GBT)Grant/award (A): 839 @ $25.37 · Option exercise (M): 9,445 · Tax withholding (F): 4,074 @ $29.87 · Option exercise (M): 9,445 (derivative) @ $0 · Grant/award (A): 72,877 (derivative) @ $0 · Grant/award (A): 72,877 (derivative) @ $0 · +1 moreEDGAR
2022-02-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 29,955 · Tax withholding (F): 10,531 @ $29.33 · Option exercise (M): 9,750 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0EDGAR
2022-01-064/AGlobal Blood Therapeutics, Inc. (GBT)Disposition to issuer (D): 24,821 @ $3.40EDGAR
2021-09-244/AGlobal Blood Therapeutics, Inc. (GBT)Option exercise (M): 29,955 · Tax withholding (F): 14,853 @ $27.33 · Option exercise (M): 9,750 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0EDGAR
2021-09-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 9,444 · Tax withholding (F): 4,683 @ $29.85 · Option exercise (M): 9,444 (derivative) @ $0EDGAR
2021-08-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 29,955 · Tax withholding (F): 14,853 @ $27.33 · Option exercise (M): 9,750 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0EDGAR
2021-06-294Royalty Pharma plc (RPRX)Grant/award (A): 5,726 @ $0EDGAR
2021-05-184Seagen Inc. (SGEN)Grant/award (A): 1,402 @ $0 · Grant/award (A): 3,462 (derivative) @ $0EDGAR
2021-03-034Global Blood Therapeutics, Inc. (GBT)Grant/award (A): 370 @ $36.21 · Grant/award (A): 132,433 (derivative) @ $0 · Grant/award (A): 75,556 (derivative) @ $0EDGAR
2021-02-034Global Blood Therapeutics, Inc. (GBT)Option exercise (M): 42,018 · Tax withholding (F): 17,893 @ $49.49 · Option exercise (M): 12,063 (derivative) @ $0 · Option exercise (M): 9,750 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Option exercise (M): 8,955 (derivative) @ $0EDGAR
2020-08-184SEATTLE GENETICS INC /WA (SGEN)Grant/award (A): 1,799 @ $0 · Grant/award (A): 4,460 (derivative) @ $0EDGAR
2020-08-174Royalty Pharma plc (RPRX)Grant/award (A): 7,280 @ $0EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-08-10 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1188919 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs